Qualigen Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
FFR$0.89+14.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance Sheets
QUALIGEN THERAPEUTICS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| (Unaudited) | ||
|---|---|---|
| June 30, | December 31, | |
| 2025 | 2024 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $331,601 | $1,174,608 |
| Prepaid expenses and other current assets | 316,576 | 1,499,219 |
| Short-term notes receivable, net of allowance for credit losses of $828,000 at June 30, 2025 and $360,000 at December 31, 2024 | 3,312,496 | 2,010,692 |
| Total current assets | 3,960,673 | 4,684,519 |
| Other assets | 2,000 | 2,000 |
| Total Assets | $3,962,673 | $4,686,519 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities | ||
| Accounts payable | $1,404,611 | $1,568,065 |
| Accrued expenses and other current liabilities | 379,633 | 170,243 |
| Warrant liabilities | 213,976 | 269,175 |
| Convertible debt | 142,069 | — |
| Promissory notes | 3,474,667 | — |
| Total current liabilities | 5,614,956 | 2,007,483 |
| Commitments and Contingencies (Note 10) | - | - |
| Stockholders’ Equity (Deficit) | ||
| Preferred stock, $0.001 par value; 15,000,000 shares authorized; 2,984 and 6,256 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | $2,790,007 | $5,716,400 |
| Common stock, $0.001 par value; 225,000,000 shares authorized; 1,635,475 and 736,431 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 66,213 | 65,314 |
| Additional paid-in capital | 122,884,659 | 119,958,897 |
| Accumulated deficit | (127,393,162) | (123,061,575) |
| Total Stockholders’ Equity (Deficit) | (1,652,283) | 2,679,036 |
| Total Liabilities & Stockholders’ Equity (Deficit) | $3,962,673 | $4,686,519 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.